{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:57:03Z","timestamp":1778201823693,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00405-021-07173-x","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T13:02:35Z","timestamp":1637931755000},"page":"1639-1644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY"],"prefix":"10.1007","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-2302","authenticated-orcid":false,"given":"Antoine","family":"Asquier-Khati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wladimir","family":"Mauhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Gendre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Durant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolaine","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Masseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"7173_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD (2014) Fabry\u2019s disease. J Neurol Sci 344:5\u201319. https:\/\/doi.org\/10.1016\/j.jns.2014.06.029","journal-title":"J Neurol Sci"},{"key":"7173_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 64:550\u2013555. https:\/\/doi.org\/10.1203\/PDR.0b013e318183f132","journal-title":"Pediatr Res"},{"key":"7173_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548. https:\/\/doi.org\/10.1097\/01.gim.0000237866.70357.c6","journal-title":"Genet Med"},{"key":"7173_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10741-014-9452-9","volume":"20","author":"BN Putko","year":"2015","unstructured":"Putko BN, Wen K, Thompson RB et al (2015) Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev 20:179\u2013191. https:\/\/doi.org\/10.1007\/s10741-014-9452-9","journal-title":"Heart Fail Rev"},{"key":"7173_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eux261","author":"S Baig","year":"2018","unstructured":"Baig S, Edward NC, Kotecha D, Liu B, Nordin S, Kozor R et al (2018) Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. EP Europace. https:\/\/doi.org\/10.1093\/europace\/eux261","journal-title":"EP Europace"},{"key":"7173_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D et al (2017) Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 28:1631\u20131641. https:\/\/doi.org\/10.1681\/ASN.2016090964","journal-title":"J Am Soc Nephrol"},{"key":"7173_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08035320600618809","volume":"95","author":"E Maier","year":"2006","unstructured":"Maier E, Osterrieder S, Whybra C et al (2006) Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr 95:30\u201338. https:\/\/doi.org\/10.1080\/08035320600618809","journal-title":"Acta Paediatr"},{"key":"7173_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5692\/clinicalneurol.cn-001246","volume":"59","author":"T Ohashi","year":"2019","unstructured":"Ohashi T (2019) Current status and future prospect of enzyme replacement therapy for Fabry disease. Rinsho Shinkeigaku 59:335\u2013338. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001246","journal-title":"Rinsho Shinkeigaku"},{"key":"7173_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ et al (2018) Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 123:416\u2013427. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014","journal-title":"Mol Genet Metab"},{"key":"7173_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X et al (2017) The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med 19:430\u2013438. https:\/\/doi.org\/10.1038\/gim.2016.122","journal-title":"Genet Med"},{"key":"7173_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-3-10","author":"DP Germain","year":"2002","unstructured":"Germain DP, Avan P, Chassaing A, Bonfils P (2002) Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet. https:\/\/doi.org\/10.1186\/1471-2350-3-10","journal-title":"BMC Med Genet"},{"key":"7173_CR12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00415-007-0575-y","volume":"254","author":"A Palla","year":"2007","unstructured":"Palla A, Hegemann S, Widmer U, Straumann D (2007) Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 254:1433\u20131442. https:\/\/doi.org\/10.1007\/s00415-007-0575-y","journal-title":"J Neurol"},{"key":"7173_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10545-014-9783-7","volume":"38","author":"EB Suntjens","year":"2015","unstructured":"Suntjens EB, Smid BE, Biegstraaten M et al (2015) Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy. J Inherit Metab Dis 38:351\u2013358. https:\/\/doi.org\/10.1007\/s10545-014-9783-7","journal-title":"J Inherit Metab Dis"},{"key":"7173_CR14","doi-asserted-by":"publisher","DOI":"10.4081\/audiores.2017.176","author":"S Carmona","year":"2017","unstructured":"Carmona S, Weinschelbaum R, Pardal A et al (2017) Neuro-otological and peripheral nerve involvement in Fabry disease. Audiol Res. https:\/\/doi.org\/10.4081\/audiores.2017.176","journal-title":"Audiol Res"},{"key":"7173_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/brain\/awl310","volume":"130","author":"M Ries","year":"2006","unstructured":"Ries M, Kim HJ, Zalewski CK et al (2006) Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130:143\u2013150. https:\/\/doi.org\/10.1093\/brain\/awl310","journal-title":"Brain"},{"key":"7173_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.revmed.2012.01.014","volume":"33","author":"M Pichon","year":"2012","unstructured":"Pichon M, Lidove O, Roudaire M-L et al (2012) Atteintes ORL de la maladie de Fabry: \u00e0 propos de 25 observations. Rev Med Interne 33:364\u2013369. https:\/\/doi.org\/10.1016\/j.revmed.2012.01.014","journal-title":"Rev Med Interne"},{"key":"7173_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0882-7","author":"M K\u00f6ping","year":"2018","unstructured":"K\u00f6ping M, Shehata-Dieler W, Schneider D et al (2018) Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-018-0882-7","journal-title":"Orphanet J Rare Dis"},{"key":"7173_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejmg.2018.01.006","volume":"61","author":"J Rodrigues","year":"2018","unstructured":"Rodrigues J, Azevedo O, Sousa N et al (2018) Inner ear involvement in Fabry disease: clinical and audiometric evaluation of a large cohort of patients followed in a reference centre. Eur J Med Genet 61:341\u2013347. https:\/\/doi.org\/10.1016\/j.ejmg.2018.01.006","journal-title":"Eur J Med Genet"},{"key":"7173_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188103","volume":"12","author":"M K\u00f6ping","year":"2017","unstructured":"K\u00f6ping M, Shehata-Dieler W, Cebulla M et al (2017) Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease. PLoS One 12:e0188103. https:\/\/doi.org\/10.1371\/journal.pone.0188103","journal-title":"PLoS One"},{"key":"7173_CR20","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/archinternmed.2011.506","volume":"171","author":"FR Lin","year":"2011","unstructured":"Lin FR (2011) Hearing loss prevalence in the United States. Arch Intern Med 171:1851. https:\/\/doi.org\/10.1001\/archinternmed.2011.506","journal-title":"Arch Intern Med"},{"key":"7173_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.revmed.2005.12.006","volume":"27","author":"D Malinvaud","year":"2006","unstructured":"Malinvaud D, Avan P, Germain DP et al (2006) La maladie de Fabry: l\u2019atteinte vasculaire multi-organe pourrait \u00e9galement int\u00e9resser la cochl\u00e9e. Rev Med Interne 27:527\u2013531. https:\/\/doi.org\/10.1016\/j.revmed.2005.12.006","journal-title":"Rev Med Interne"},{"key":"7173_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/0194599810395079","volume":"144","author":"K Parham","year":"2011","unstructured":"Parham K, McKinnon BJ, Eibling D, Gates GA (2011) Challenges and opportunities in presbycusis. Otolaryngol Head Neck Surg 144:491\u2013495. https:\/\/doi.org\/10.1177\/0194599810395079","journal-title":"Otolaryngol Head Neck Surg"},{"key":"7173_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/archotol.1996.01890140047010","volume":"122","author":"GA Gates","year":"1996","unstructured":"Gates GA, Cobb JL, Linn RT et al (1996) Central auditory dysfunction, cognitive dysfunction, and dementia in older people. Arch Otolaryngol Head Neck Surg 122:161\u2013167. https:\/\/doi.org\/10.1001\/archotol.1996.01890140047010","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"7173_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225071","volume":"14","author":"PD Yazdanfard","year":"2019","unstructured":"Yazdanfard PD, Madsen CV, Nielsen LH et al (2019) Significant hearing loss in Fabry disease: study of the Danish nationwide cohort prior to treatment. PLoS One 14:e0225071. https:\/\/doi.org\/10.1371\/journal.pone.0225071","journal-title":"PLoS One"},{"key":"7173_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ (2015) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther 23:1138\u20131148. https:\/\/doi.org\/10.1038\/mt.2015.62","journal-title":"Mol Ther"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-021-07173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-021-07173-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-021-07173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T03:08:28Z","timestamp":1646449708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-021-07173-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["7173"],"URL":"https:\/\/doi.org\/10.1007\/s00405-021-07173-x","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"19 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WM and OL received travel fees or speaking honoraria from Shire-Takeda, Amicus Therapeutics and Sanofi-Genzyme. CL received travel fees or speaking honoraria from Sanofi-Genzyme. HM received travel fees or speaking honoraria from Shire-Takeda, Amicus Therapeutics and Sanofi-Genzyme. DL received travel fees or board or speaking honoraria from Shire-Takeda, Amicus Therapeutics and Sanofi-Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained when patients were included in the FFABRY cohort. An information sheet was sent to patients when adding ENT to FFABRY register.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have read the final version of the manuscript and agree with its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}